Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Myriad Genetics has a 12-month low of $7.35 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.1, ...

Good morning! Citigroup in the middle of funding freeze fallout, Ursula von der Leyen offers Trump a “zero-for-zero” tariffs ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...

Guggenheim downgraded Myriad Genetics (MYGN) to Neutral from Buy without a price target Based on key opinion leader checks on GeneSight and ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen ...

The "Genetic Screening Testing for Reproductive Health Market - A Global and Regional Analysis: Focus on Test Type, Application, Technology, End User, and Country-Level Analysis - Analysis and ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...